1,721,006 research outputs found
Cytotoxic T lymphocyte epitope analogues containing cis- or trans-4-aminocyclohexanecarboxylic acid residues
No full textIn order to improve the immunotherapeutical potential of H-Cys-Leu-Gly-Gly-Leu-Leu-Thr-Met-Val-OH (CLG) peptide, an Epstein-Barr virus (EBV) subdominant epitope derived from the membrane protein LMP2, we have synthesized and tested CLG analogues containing cis- and/or trans-4-aminocyclohexanecarboxylic acid (ACCA) replacing Gly-Gly and/or Thr-Met dipeptide units. All pseudopeptides were tested for metabolic stability and for their capacity to bind HLA-A2 molecules and to sensitize target cells to lysis. All new compounds exhibited higher enzymatic resistance compared to the original CLG and some trans-ACCA-derivatives were able to associate HLA-A2 and to efficiently stimulate CTL responses directed against the CLG natural epitope
Opioid peptides. Synthesis and biological properties of dermorphin related hexapeptides
No full textThe Gly 4 and/or Tyr 5 residues in dermorphin hexapeptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-OH) were replaced by Nα-methyl- or D-amino acids in order to examine the effect on opioid activity. Two pseudopeptides (H-Tyr-D-Ala-Phe-Gly-ψ (NHCO)-Xaa-Pro-OH, Xaa - Tyr or Phe) in which the Gly 4-Xaa bond is reversed, were also prepared. Metabolic stability, analgesia and selectivity of these compounds for different receptor populations have been investigated. Results suggest that the 12 new analogues showed a negligible affinity for the K binding site and some selectivity for μ- or δ receptors. In some cases the analgesic potencies seems to be related to enzymatic stability of the peptides
Synthesis and opioid activity of dermorphin tetrapeptides beearing D-methionine S-oxide at position 2
No full textEight new dermorphin tetrapeptides, X-Tyr-D-MetO-Phe-aa-Y (X = H, H2N = C(NH); aa = Gly, 2-aminoethanol, sarcosine; Y = NH2, NH-alkyl), were prepared and tested for opioid activity. They show dose-related naloxone-reversible opioid effects in vitro and in vivo. H-Tyr-D-MetO-Phe-Gly-NH2 (I) (guinea pig ileum IC50 = 13.6 nM; tail-flick ED50 = 1.97 pmol/mouse, icv, and 0.65 mumol/kg, sc), though less effective in the periphery, has central activities higher than those of dermorphin H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. Following intracerebroventricular or subcutaneous administrations in mice, I is about respectively 1500 and 17 times as potent an analgesic as morphine
Structure-activity relatioships of dermorphin tetrapeptides carrying a ketomethylene linkage
No full textThe synthesis and in vitro pharmacological tests of 5 ketomethylene tetrapeptide analogues of the opioid heptapeptide dermorphin H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 are described in this study. The substitution of the original Phe-Gly peptide bond (-CO-NH-) by the ketomethylene linkage (-CO-CH2-) provided analogues with reduced opioid activity
Opioid peptides. Synthesis and binding assays of desamino-Tyr1 dermorphin analogues. XII
No full textEight new dermorphin peptides, X-C6H4-CH2CH2CO-D-Ala-Phe-(L or D)-Yaa-NH2 [X = H, OH; Y = lysine, homoarginine (Har)], were prepared and tested by binding assays. They show negligible affinity for mu-, delta- and K-receptor sites. These findings indicate that the N-terminal ammonium group can not be replaced by the ammonium or guanidinium function located at the side-chain in Lys or Har derivatives
Opioid peptides: Structure-activity relationships of dermorphin endothiotetrapeptides. VII
No full textWe describe the synthesis and preliminary in vitro and in vivo pharmacological tests of five endothiotetrapeptide analogues of the opioid heptapeptide dermorphin H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser.-NH2. The modification obtained by substituting Phet for Phe3 or Glyt for Gly4 provided further analogues with significant opioid activity
Synthesis and activity of dermorphin-growth hormone releasing factor hybrid peptides
No full textDermorphin- growth hormone releasing factor (GRF) hybrid peptides (Y-Tyr-D-Ala-Xaa-Gly-Tyr-Pro-Ser-NH2) were synthesized and tested for opioid activity and their ability to stimulate growth hormone (GH) secretion. The substitution of Phe3 for Asp and Glu in dermorphin or its N-terminal acetylation produced peptides with no affinity for opioid receptors but significant, even if low, GRF-like activity
Synthesis and opioid activity of partially retro-inverso analogs of dermorphin
No full textWe studied the effect of partial retro-inverso modification of selected peptide bonds of dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. The modifications concern two consecutive peptide bonds (Phe3-Cly4-Tyr5, I) or a single one (Gly4-Tyr5-, II or Phe3-Gly4, III). All pseudoheptapeptides showed low opioid activity in the in vitro and in vivo tests. Compound III has a biological potency comparable to that of morphine but only 2-5% of original dermorphin when tested in guinea pig ileum preparation and in mice tail-flick assay after intracerebro or subcutaneous administration
Opioid peptides. VIII. Synthesis and preliminary biological activity of [D-Phe3]- or [alpha,beta-dehydro-Phe3]dermorphin tetrapeptides
No full textWe describe the synthesis and preliminary in vitro pharmacological testing of two new tetrapeptide analogues of the opioid heptapeptide dermorphin H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. The replacement of Phe3 by its D-enantiomer was hardly if at all tolerated. The unsaturated analogue carrying the phenyl ring of the delta Phe3 residue in the Z-configuration, was almost inactive
- …
